Safety and immunogenicity of a candidate parvovirus B19 vaccine

Vaccine

Volumn 29, Issue 43, 2011, Pages 7357-7363

  Bernstein, David I ^a   El Sahly, Hana M ^b   Keitel, Wendy A ^b   Wolff, Mark ^c   Simone, Gina ^c   Segawa, Claire ^c   Wong, Susan ^d   Shelly, Daniel ^e   Young, Neal S ^d   Dempsey, Walla ^f  

^a UNIVERSITY OF CINCINNATI   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c EMMES CORPORATION   (United States)

^d NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^e Meridian Bioscience Inc   (United States)

^f NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

B19; MF59; Parvovirus; Vaccine; VLP

Indexed keywords

MIFAMURTIDE; NEUTRALIZING ANTIBODY; RECOMBINANT PARVOVIRUS B19 VACCINE; RECOMBINANT VACCINE; UNCLASSIFIED DRUG; VIRUS VACCINE;

ADULT; ARTHRALGIA; ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG SCREENING; ERYTHEMA; FEMALE; FEVER; HEADACHE; HUMAN; HUMAN EXPERIMENT; IMMUNOGENICITY; INJECTION SITE REACTION; MALAISE; MALE; MYALGIA; NONHUMAN; NORMAL HUMAN; PAIN; PARVOVIRUS INFECTION; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VACCINATION REACTION;

ADOLESCENT; ADULT; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CAPSID PROTEINS; DOUBLE-BLIND METHOD; ERYTHEMA INFECTIOSUM; EXANTHEMA; FEMALE; HUMANS; MALE; MIDDLE AGED; PARVOVIRUS B19, HUMAN; VACCINES, SYNTHETIC; VIRAL VACCINES;

EID: 80053436637     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.07.080     Document Type: Article

References (19)

1. Young N.S., Brown K.E. Parvovirus B19. N Engl J Med 2004, 350(February (6)):586-597.
2. Breinholt J.P., Moulik M., Dreyer W.J., Denfield S.W., Kim J.J., Jefferies J.L., et al. Viral epidemiologic shift in inflammatory heart disease: the increasing involvement of parvovirus B19 in the myocardium of pediatric cardiac transplant patients. J Heart Lung Transplant 2010, 29(July (7)):739-746.
3. Bock C.T., Klingel K., Kandolf R. Human parvovirus B19-associated myocarditis. N Engl J Med 2010, 362(April (13)):1248-1249.
4. Serjeant G.R., Serjeant B.E., Thomas P.W., Anderson M.J., Patou G., Pattison J.R. Human parvovirus infection in homozygous sickle cell disease. Lancet 1993, 341(May (8855)):1237-1240.
5. Wildig J., Michon P., Siba P., Mellombo M., Ura A., Mueller I., et al. Parvovirus B19 infection contributes to severe anemia in young children in Papua New Guinea. J Infect Dis 2006, 194(July (2)):146-153.
6. Wildig J., Cossart Y., Peshu N., Gicheru N., Tuju J., Williams T.N., et al. Parvovirus B19 infection and severe anaemia in Kenyan children: a retrospective case control study. BMC Infect Dis 2010, 10:88.
7. Bultmann B.D., Klingel K., Sotlar K., Bock C.T., Kandolf R. Parvovirus B19: a pathogen responsible for more than hematologic disorders. Virchows Arch 2003, 442(January (1)):8-17.
8. Broliden K., Tolfvenstam T., Norbeck O. Clinical aspects of parvovirus B19 infection. J Intern Med 2006, 260(October (4)):285-304.
9. Mossong J., Hens N., Friederichs V., Davidkin I., Broman M., Litwinska B., et al. Parvovirus B19 infection in five European countries: seroepidemiology, force of infection and maternal risk of infection. Epidemiol Infect 2008, 136(August (8)):1059-1068.
10. Kajigaya S., Fujii H., Field A., Anderson S., Rosenfeld S., Anderson L.J., et al. Self-assembled B19 parvovirus capsids, produced in a baculovirus system, are antigenically and immunogenically similar to native virions. Proc Natl Acad Sci U S A 1991, 88(June (11)):4646-4650.
11. Ballou W.R., Reed J.L., Noble W., Young N.S., Koenig S. Safety and immunogenicity of a recombinant parvovirus B19 vaccine formulated with MF59C.1. J Infect Dis 2003, 187(February (4)):675-678.
12. Bansal G.P., Hatfield J.A., Dunn F.E., Kramer A.A., Brady F., Riggin C.H., et al. Candidate recombinant vaccine for human B19 parvovirus. J Infect Dis 1993, 167(May (5)):1034-1044.
13. Cox M.M., Patriarca P.A., Treanor J., FluBlok a recombinant hemagglutinin influenza vaccine. Influenza Other Resp Viruses 2008, 2(November (6)):211-219.
14. El Sahly H. MF59 as a vaccine adjuvant: a review of safety and immunogenicity. Expert Rev Vaccines 2010, 9(October (10)):1135-1141.
15. Wong S., Brown K.E. Development of an improved method of detection of infectious parvovirus B19. J Clin Virol 2006, 35(April (4)):407-413.
16. Dorsch S., Liebisch G., Kaufmann B., von Landenberg P., Hoffmann J.H., Drobnik W., et al. The VP1 unique region of parvovirus B19 and its constituent phospholipase A2-like activity. J Virol 2002, 76(February (4)):2014-2018.
17. Rodriguez De Turco E.B., Jackson F.R., DeCoster M.A., Kolko M., Bazan N.G. Glutamate signalling and secretory phospholipase A2 modulate the release of arachidonic acid from neuronal membranes. J Neurosci Res 2002, 68(June (5)):558-567.
18. Muller U.R., Dudler T., Schneider T., Crameri R., Fischer H., Skrbic D., et al. Type I skin reactivity to native and recombinant phospholipase A2 from honeybee venom is similar. J Allergy Clin Immunol 1995, 96(September (3)):395-402.
19. Soldatova L.N., Crameri R., Gmachl M., Kemeny D.M., Schmidt M., Weber M., et al. Superior biologic activity of the recombinant bee venom allergen hyaluronidase expressed in baculovirus-infected insect cells as compared with Escherichia coli. J Allergy Clin Immunol 1998, 101(May (5)):691-698.